Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib First-Line in CLL With Subclonal TP53 Aberrations
2024-514823-41-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: TP53 mutated subclone size over time. Planned start Aug 2024; status: authorised.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-514823-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514823-41-00.